Renal Cell Carcinoma – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of renal cell carcinoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s renal cell carcinoma forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of renal cell carcinoma events per year?
- Of all people diagnosed with renal cell carcinoma, how many in each country are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of renal cell carcinoma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
In total, Clarivate Epidemiology forecasts 27 renal cell carcinoma patient populations, as follows:
- Diagnosed incident cases.
- Diagnosed incident cases by stage.
- Diagnosed incident cases of metastatic recurrent disease.
- Diagnosed prevalent cases.
- Diagnosed early-stage (stages I-III) drug-treated population.
- Diagnosed first-line metastatic drug-treatable population.
- Diagnosed first-line metastatic drug-treated population.
- Diagnosed second-line metastatic drug-treatable population.
- Diagnosed second-line metastatic drug-treated population.
- Diagnosed third-line metastatic drug-treatable population.
- Diagnosed third-line metastatic drug-treated population.
- Diagnosed fourth-line metastatic drug-treatable population.
- Diagnosed fourth-line metastatic drug-treated population.
- … and many more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Renal Cell Carcinoma - Epidemiology - Emerging Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of renal cell carcinoma)
- Diagnosed incident cases
- Stage distribution of renal cell carcinoma
- Histology subtype
- Recurrent incident cases of renal cell carcinoma
- Diagnosed prevalent cases
- Drug-treatable populations
- Drug-treated populations
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviation table
Katie Myatt, M.S., Senior Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Myatt worked as an epidemiologist for local and state public health departments performing infectious disease surveillance, both endemic and epidemic. Her interests are infectious disease epidemiology and cancer epidemiology. She received both her master’s degree in epidemiology and her bachelor’s degree in biology from the University of Louisville in Kentucky.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.